- Lisaftoclax (APG-2575) secures its first-ever recommendation in the CSCO 2025 Guidelines, marking a milestone for China-developed Bcl-2 inhibitors.
- Olverembatinib receives an upgraded Level I recommendation for treating children with Ph+ ALL, enhancing pediatric oncology options.
- Inclusion in China's National Reimbursement Drug List supports wider accessibility of olverembatinib, jointly commercialized with Innovent Biologics.
Ascentage Pharma (AAPG, Financial) has announced a significant milestone with the inclusion of its proprietary drugs, lisaftoclax and olverembatinib, in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. This achievement underscores the clinical promise of these therapies in treating various hematological malignancies.
Lisaftoclax (APG-2575), a novel Bcl-2 selective inhibitor, has been endorsed by the CSCO Guidelines for the first time for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It stands as the only Bcl-2 inhibitor developed in China to achieve this recognition, also having received a Priority Review designation from the China National Medical Product Administration (NMPA) in November 2024.
Olverembatinib, the company's next-generation tyrosine kinase inhibitor (TKI), has been upgraded to a Level I recommendation in the CSCO Guidelines for treating pediatric patients with Ph+ acute lymphoblastic leukemia (ALL) harboring the T315I mutation. Already commercially available, olverembatinib is included in China's National Reimbursement Drug List, promoting its accessibility and enhancing revenue potential.
Joint commercialization with Innovent Biologics strengthens the strategic positioning of olverembatinib in the Chinese market. This collaboration alongside the CSCO recognition reflects the robust clinical data supporting Ascentage Pharma's drugs, further validating their therapeutic potential in hematological malignancies.
For more information, visit Ascentage Pharma's official site.
